Congress is unlikely to clear any major reform of the 340B in the remaining months of 2023, unless spurred by [...] …
Category: Federal
Drug maker Boehringer Ingelheim (BI) sued the federal government to block Medicare price negotiations shortly before the Department of Health [...] …
The congressional sponsor of legislation that would require hospitals and potentially other covered entities to publicly report their 340B revenue, [...] …
The Department of Health and Human Services (HHS) today announced the first 10 prescription drugs eligible for Medicare price negotiations [...] …
The boards of directors of health centers need to take on a bigger advocacy role in support of the 340B [...] …
The nation’s largest hospital advocacy organization urged legislators to drop a provision from draft legislation that would exclude generic injectables [...] …
The hiring of lobbyists in the congressional legislative fight over 340B was dominated by pharmaceutical firms and provider-manufacturer alliances in [...] …
Congress should let for-profit hospitals into the 340B drug pricing program as “a long overdue evolutionary step” that will advance [...] …
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...] …
Twenty-three state attorneys general urged a group of U.S. senators crafting a legislative overhaul of the 340B program to add [...] …